INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17201, 21917, 'Pitavastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17202, 21918, 'Pitavastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17203, 21961, 'Pitavastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17204, 24964, 'Pitavastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17205, 24966, 'Pitavastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17206, 24968, 'Pitavastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17207, 33109, 'Pitavastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17208, 33110, 'Pitavastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17209, 21113, 'Pitavastatin', 'Kidney Diseases', 'Some HMG-CoA reductase inhibitors such as fluvastatin, have not been studied in patients with severe renal impairment or end-stage renal disease.  Some others such as pitavastatin and simvastatin, require a dose reduction when used in this group of patients.  Caution and close monitoring is advised when using these drugs in patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17210, 21114, 'Pitavastatin', 'Kidney Diseases', 'Some HMG-CoA reductase inhibitors such as fluvastatin, have not been studied in patients with severe renal impairment or end-stage renal disease.  Some others such as pitavastatin and simvastatin, require a dose reduction when used in this group of patients.  Caution and close monitoring is advised when using these drugs in patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17211, 21115, 'Pitavastatin', 'Kidney Diseases', 'Some HMG-CoA reductase inhibitors such as fluvastatin, have not been studied in patients with severe renal impairment or end-stage renal disease.  Some others such as pitavastatin and simvastatin, require a dose reduction when used in this group of patients.  Caution and close monitoring is advised when using these drugs in patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17212, 21871, 'Pitavastatin', 'Kidney Diseases', 'Some HMG-CoA reductase inhibitors such as fluvastatin, have not been studied in patients with severe renal impairment or end-stage renal disease.  Some others such as pitavastatin and simvastatin, require a dose reduction when used in this group of patients.  Caution and close monitoring is advised when using these drugs in patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17213, 21872, 'Pitavastatin', 'Kidney Diseases', 'Some HMG-CoA reductase inhibitors such as fluvastatin, have not been studied in patients with severe renal impairment or end-stage renal disease.  Some others such as pitavastatin and simvastatin, require a dose reduction when used in this group of patients.  Caution and close monitoring is advised when using these drugs in patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17214, 21873, 'Pitavastatin', 'Kidney Diseases', 'Some HMG-CoA reductase inhibitors such as fluvastatin, have not been studied in patients with severe renal impairment or end-stage renal disease.  Some others such as pitavastatin and simvastatin, require a dose reduction when used in this group of patients.  Caution and close monitoring is advised when using these drugs in patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17215, 21917, 'Pitavastatin', 'Kidney Diseases', 'Some HMG-CoA reductase inhibitors such as fluvastatin, have not been studied in patients with severe renal impairment or end-stage renal disease.  Some others such as pitavastatin and simvastatin, require a dose reduction when used in this group of patients.  Caution and close monitoring is advised when using these drugs in patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17216, 21918, 'Pitavastatin', 'Kidney Diseases', 'Some HMG-CoA reductase inhibitors such as fluvastatin, have not been studied in patients with severe renal impairment or end-stage renal disease.  Some others such as pitavastatin and simvastatin, require a dose reduction when used in this group of patients.  Caution and close monitoring is advised when using these drugs in patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17217, 21961, 'Pitavastatin', 'Kidney Diseases', 'Some HMG-CoA reductase inhibitors such as fluvastatin, have not been studied in patients with severe renal impairment or end-stage renal disease.  Some others such as pitavastatin and simvastatin, require a dose reduction when used in this group of patients.  Caution and close monitoring is advised when using these drugs in patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17218, 24964, 'Pitavastatin', 'Kidney Diseases', 'Some HMG-CoA reductase inhibitors such as fluvastatin, have not been studied in patients with severe renal impairment or end-stage renal disease.  Some others such as pitavastatin and simvastatin, require a dose reduction when used in this group of patients.  Caution and close monitoring is advised when using these drugs in patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17219, 24966, 'Pitavastatin', 'Kidney Diseases', 'Some HMG-CoA reductase inhibitors such as fluvastatin, have not been studied in patients with severe renal impairment or end-stage renal disease.  Some others such as pitavastatin and simvastatin, require a dose reduction when used in this group of patients.  Caution and close monitoring is advised when using these drugs in patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17220, 24968, 'Pitavastatin', 'Kidney Diseases', 'Some HMG-CoA reductase inhibitors such as fluvastatin, have not been studied in patients with severe renal impairment or end-stage renal disease.  Some others such as pitavastatin and simvastatin, require a dose reduction when used in this group of patients.  Caution and close monitoring is advised when using these drugs in patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17221, 33109, 'Pitavastatin', 'Kidney Diseases', 'Some HMG-CoA reductase inhibitors such as fluvastatin, have not been studied in patients with severe renal impairment or end-stage renal disease.  Some others such as pitavastatin and simvastatin, require a dose reduction when used in this group of patients.  Caution and close monitoring is advised when using these drugs in patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17222, 33110, 'Pitavastatin', 'Kidney Diseases', 'Some HMG-CoA reductase inhibitors such as fluvastatin, have not been studied in patients with severe renal impairment or end-stage renal disease.  Some others such as pitavastatin and simvastatin, require a dose reduction when used in this group of patients.  Caution and close monitoring is advised when using these drugs in patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17223, 3550, 'Polymyxin B', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17224, 17417, 'Polymyxin B', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17225, 17429, 'Polymyxin B', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17226, 17430, 'Polymyxin B', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17227, 17436, 'Polymyxin B', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17228, 21026, 'Polymyxin B', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17229, 21105, 'Polymyxin B', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17230, 22407, 'Polymyxin B', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17231, 23390, 'Polymyxin B', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17232, 3550, 'Polymyxin B', 'Kidney Diseases', 'Albuminuria, cellular casts/cylindruria, and azotemia are generally seen in patients with nephrotoxicity due to polymyxin B sulfate; nephrotoxic reactions have also included rising blood levels without any increase in dosage.  Renal function should be carefully determined, and the dosage should be reduced in patients with renal damage and nitrogen retention.  Polymyxin B sulfate should be discontinued if urine output decreases and BUN increases.Neurotoxic reactions with polymyxin B sulfate may be shown by drowsiness, irritability, weakness, perioral paresthesia, numbness of the extremities, ataxia, and blurring of vision; such reactions are generally associated with high serum levels found in patients with impaired renal function and/or nephrotoxicity.  The neurotoxicity of polymyxin B sulfate can lead to respiratory paralysis from neuromuscular blockade, particularly when administered soon after anesthesia and/or muscle relaxants.  If signs of respiratory paralysis develop, respiration should be assisted as required and polymyxin B sulfate should be discontinued.Baseline renal function should be determined before therapy, and renal function and blood polymyxin B sulfate levels should be monitored frequently during parenteral therapy.  Coadministration with or sequential use of other neurotoxic and/or nephrotoxic agents should be avoided.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17233, 17417, 'Polymyxin B', 'Kidney Diseases', 'Albuminuria, cellular casts/cylindruria, and azotemia are generally seen in patients with nephrotoxicity due to polymyxin B sulfate; nephrotoxic reactions have also included rising blood levels without any increase in dosage.  Renal function should be carefully determined, and the dosage should be reduced in patients with renal damage and nitrogen retention.  Polymyxin B sulfate should be discontinued if urine output decreases and BUN increases.Neurotoxic reactions with polymyxin B sulfate may be shown by drowsiness, irritability, weakness, perioral paresthesia, numbness of the extremities, ataxia, and blurring of vision; such reactions are generally associated with high serum levels found in patients with impaired renal function and/or nephrotoxicity.  The neurotoxicity of polymyxin B sulfate can lead to respiratory paralysis from neuromuscular blockade, particularly when administered soon after anesthesia and/or muscle relaxants.  If signs of respiratory paralysis develop, respiration should be assisted as required and polymyxin B sulfate should be discontinued.Baseline renal function should be determined before therapy, and renal function and blood polymyxin B sulfate levels should be monitored frequently during parenteral therapy.  Coadministration with or sequential use of other neurotoxic and/or nephrotoxic agents should be avoided.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17234, 17429, 'Polymyxin B', 'Kidney Diseases', 'Albuminuria, cellular casts/cylindruria, and azotemia are generally seen in patients with nephrotoxicity due to polymyxin B sulfate; nephrotoxic reactions have also included rising blood levels without any increase in dosage.  Renal function should be carefully determined, and the dosage should be reduced in patients with renal damage and nitrogen retention.  Polymyxin B sulfate should be discontinued if urine output decreases and BUN increases.Neurotoxic reactions with polymyxin B sulfate may be shown by drowsiness, irritability, weakness, perioral paresthesia, numbness of the extremities, ataxia, and blurring of vision; such reactions are generally associated with high serum levels found in patients with impaired renal function and/or nephrotoxicity.  The neurotoxicity of polymyxin B sulfate can lead to respiratory paralysis from neuromuscular blockade, particularly when administered soon after anesthesia and/or muscle relaxants.  If signs of respiratory paralysis develop, respiration should be assisted as required and polymyxin B sulfate should be discontinued.Baseline renal function should be determined before therapy, and renal function and blood polymyxin B sulfate levels should be monitored frequently during parenteral therapy.  Coadministration with or sequential use of other neurotoxic and/or nephrotoxic agents should be avoided.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17235, 17430, 'Polymyxin B', 'Kidney Diseases', 'Albuminuria, cellular casts/cylindruria, and azotemia are generally seen in patients with nephrotoxicity due to polymyxin B sulfate; nephrotoxic reactions have also included rising blood levels without any increase in dosage.  Renal function should be carefully determined, and the dosage should be reduced in patients with renal damage and nitrogen retention.  Polymyxin B sulfate should be discontinued if urine output decreases and BUN increases.Neurotoxic reactions with polymyxin B sulfate may be shown by drowsiness, irritability, weakness, perioral paresthesia, numbness of the extremities, ataxia, and blurring of vision; such reactions are generally associated with high serum levels found in patients with impaired renal function and/or nephrotoxicity.  The neurotoxicity of polymyxin B sulfate can lead to respiratory paralysis from neuromuscular blockade, particularly when administered soon after anesthesia and/or muscle relaxants.  If signs of respiratory paralysis develop, respiration should be assisted as required and polymyxin B sulfate should be discontinued.Baseline renal function should be determined before therapy, and renal function and blood polymyxin B sulfate levels should be monitored frequently during parenteral therapy.  Coadministration with or sequential use of other neurotoxic and/or nephrotoxic agents should be avoided.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17236, 17436, 'Polymyxin B', 'Kidney Diseases', 'Albuminuria, cellular casts/cylindruria, and azotemia are generally seen in patients with nephrotoxicity due to polymyxin B sulfate; nephrotoxic reactions have also included rising blood levels without any increase in dosage.  Renal function should be carefully determined, and the dosage should be reduced in patients with renal damage and nitrogen retention.  Polymyxin B sulfate should be discontinued if urine output decreases and BUN increases.Neurotoxic reactions with polymyxin B sulfate may be shown by drowsiness, irritability, weakness, perioral paresthesia, numbness of the extremities, ataxia, and blurring of vision; such reactions are generally associated with high serum levels found in patients with impaired renal function and/or nephrotoxicity.  The neurotoxicity of polymyxin B sulfate can lead to respiratory paralysis from neuromuscular blockade, particularly when administered soon after anesthesia and/or muscle relaxants.  If signs of respiratory paralysis develop, respiration should be assisted as required and polymyxin B sulfate should be discontinued.Baseline renal function should be determined before therapy, and renal function and blood polymyxin B sulfate levels should be monitored frequently during parenteral therapy.  Coadministration with or sequential use of other neurotoxic and/or nephrotoxic agents should be avoided.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17237, 21026, 'Polymyxin B', 'Kidney Diseases', 'Albuminuria, cellular casts/cylindruria, and azotemia are generally seen in patients with nephrotoxicity due to polymyxin B sulfate; nephrotoxic reactions have also included rising blood levels without any increase in dosage.  Renal function should be carefully determined, and the dosage should be reduced in patients with renal damage and nitrogen retention.  Polymyxin B sulfate should be discontinued if urine output decreases and BUN increases.Neurotoxic reactions with polymyxin B sulfate may be shown by drowsiness, irritability, weakness, perioral paresthesia, numbness of the extremities, ataxia, and blurring of vision; such reactions are generally associated with high serum levels found in patients with impaired renal function and/or nephrotoxicity.  The neurotoxicity of polymyxin B sulfate can lead to respiratory paralysis from neuromuscular blockade, particularly when administered soon after anesthesia and/or muscle relaxants.  If signs of respiratory paralysis develop, respiration should be assisted as required and polymyxin B sulfate should be discontinued.Baseline renal function should be determined before therapy, and renal function and blood polymyxin B sulfate levels should be monitored frequently during parenteral therapy.  Coadministration with or sequential use of other neurotoxic and/or nephrotoxic agents should be avoided.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17238, 21105, 'Polymyxin B', 'Kidney Diseases', 'Albuminuria, cellular casts/cylindruria, and azotemia are generally seen in patients with nephrotoxicity due to polymyxin B sulfate; nephrotoxic reactions have also included rising blood levels without any increase in dosage.  Renal function should be carefully determined, and the dosage should be reduced in patients with renal damage and nitrogen retention.  Polymyxin B sulfate should be discontinued if urine output decreases and BUN increases.Neurotoxic reactions with polymyxin B sulfate may be shown by drowsiness, irritability, weakness, perioral paresthesia, numbness of the extremities, ataxia, and blurring of vision; such reactions are generally associated with high serum levels found in patients with impaired renal function and/or nephrotoxicity.  The neurotoxicity of polymyxin B sulfate can lead to respiratory paralysis from neuromuscular blockade, particularly when administered soon after anesthesia and/or muscle relaxants.  If signs of respiratory paralysis develop, respiration should be assisted as required and polymyxin B sulfate should be discontinued.Baseline renal function should be determined before therapy, and renal function and blood polymyxin B sulfate levels should be monitored frequently during parenteral therapy.  Coadministration with or sequential use of other neurotoxic and/or nephrotoxic agents should be avoided.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17239, 22407, 'Polymyxin B', 'Kidney Diseases', 'Albuminuria, cellular casts/cylindruria, and azotemia are generally seen in patients with nephrotoxicity due to polymyxin B sulfate; nephrotoxic reactions have also included rising blood levels without any increase in dosage.  Renal function should be carefully determined, and the dosage should be reduced in patients with renal damage and nitrogen retention.  Polymyxin B sulfate should be discontinued if urine output decreases and BUN increases.Neurotoxic reactions with polymyxin B sulfate may be shown by drowsiness, irritability, weakness, perioral paresthesia, numbness of the extremities, ataxia, and blurring of vision; such reactions are generally associated with high serum levels found in patients with impaired renal function and/or nephrotoxicity.  The neurotoxicity of polymyxin B sulfate can lead to respiratory paralysis from neuromuscular blockade, particularly when administered soon after anesthesia and/or muscle relaxants.  If signs of respiratory paralysis develop, respiration should be assisted as required and polymyxin B sulfate should be discontinued.Baseline renal function should be determined before therapy, and renal function and blood polymyxin B sulfate levels should be monitored frequently during parenteral therapy.  Coadministration with or sequential use of other neurotoxic and/or nephrotoxic agents should be avoided.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17240, 23390, 'Polymyxin B', 'Kidney Diseases', 'Albuminuria, cellular casts/cylindruria, and azotemia are generally seen in patients with nephrotoxicity due to polymyxin B sulfate; nephrotoxic reactions have also included rising blood levels without any increase in dosage.  Renal function should be carefully determined, and the dosage should be reduced in patients with renal damage and nitrogen retention.  Polymyxin B sulfate should be discontinued if urine output decreases and BUN increases.Neurotoxic reactions with polymyxin B sulfate may be shown by drowsiness, irritability, weakness, perioral paresthesia, numbness of the extremities, ataxia, and blurring of vision; such reactions are generally associated with high serum levels found in patients with impaired renal function and/or nephrotoxicity.  The neurotoxicity of polymyxin B sulfate can lead to respiratory paralysis from neuromuscular blockade, particularly when administered soon after anesthesia and/or muscle relaxants.  If signs of respiratory paralysis develop, respiration should be assisted as required and polymyxin B sulfate should be discontinued.Baseline renal function should be determined before therapy, and renal function and blood polymyxin B sulfate levels should be monitored frequently during parenteral therapy.  Coadministration with or sequential use of other neurotoxic and/or nephrotoxic agents should be avoided.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17241, 3595, 'Potassium acetate', 'Liver Diseases', 'Solutions containing acetate ion should be administered cautiously in patients with conditions where there may be an increased level or an impaired utilization of this ion, such as severe hepatic insufficiency.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17242, 7723, 'Potassium acetate', 'Liver Diseases', 'Solutions containing acetate ion should be administered cautiously in patients with conditions where there may be an increased level or an impaired utilization of this ion, such as severe hepatic insufficiency.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17243, 15668, 'Potassium acetate', 'Liver Diseases', 'Solutions containing acetate ion should be administered cautiously in patients with conditions where there may be an increased level or an impaired utilization of this ion, such as severe hepatic insufficiency.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17244, 3595, 'Potassium acetate', 'Dehydration', 'Administration of potassium salts in severe dehydration may predispose to renal impairment.  Therapy with potassium salts should be administered cautiously in patients with acute dehydration (e.g., due to severe or prolonged diarrhea or heat stress).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17245, 7723, 'Potassium acetate', 'Dehydration', 'Administration of potassium salts in severe dehydration may predispose to renal impairment.  Therapy with potassium salts should be administered cautiously in patients with acute dehydration (e.g., due to severe or prolonged diarrhea or heat stress).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17246, 15668, 'Potassium acetate', 'Dehydration', 'Administration of potassium salts in severe dehydration may predispose to renal impairment.  Therapy with potassium salts should be administered cautiously in patients with acute dehydration (e.g., due to severe or prolonged diarrhea or heat stress).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17247, 3595, 'Potassium acetate', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17248, 7723, 'Potassium acetate', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17249, 15668, 'Potassium acetate', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17250, 3595, 'Potassium acetate', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17251, 7723, 'Potassium acetate', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17252, 15668, 'Potassium acetate', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17253, 3595, 'Potassium acetate', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17254, 7723, 'Potassium acetate', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17255, 15668, 'Potassium acetate', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17256, 3595, 'Potassium acetate', 'Alkalosis', 'Hypokalemia in patients with metabolic or respiratory alkalosis should generally be treated with potassium chloride rather than an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate), since alkali therapy may exacerbate the condition.  In addition, hypochloremia may accompany alkalosis, which is best treated with potassium chloride.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17257, 7723, 'Potassium acetate', 'Alkalosis', 'Hypokalemia in patients with metabolic or respiratory alkalosis should generally be treated with potassium chloride rather than an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate), since alkali therapy may exacerbate the condition.  In addition, hypochloremia may accompany alkalosis, which is best treated with potassium chloride.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17258, 15668, 'Potassium acetate', 'Alkalosis', 'Hypokalemia in patients with metabolic or respiratory alkalosis should generally be treated with potassium chloride rather than an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate), since alkali therapy may exacerbate the condition.  In addition, hypochloremia may accompany alkalosis, which is best treated with potassium chloride.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17259, 0, 'Ponatinib', 'Liver Failure', 'Hepatotoxicity, liver failure and death have occurred in ponatinib-treated patients.  Interrupt ponatinib if hepatotoxicity is suspected.  It is recommended to monitor hepatic function and to administer ponatinib at a dose of 30 mg once daily in patients with hepatic impairment.  Care should be exercised when using ponatinib in patients with hepatic impairment as the safety of multiple doses, or doses higher than 30 mg have not been studied in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17260, 0, 'Ponatinib', 'Cardiovascular Diseases', 'Cardiovascular events, including arterial vascular occlusive events, peripheral arterial occlusive events and ischemic cerebrovascular events have been reported in patients receiving tyrosine kinase inhibitors.  If acute signs or symptoms of cardiovascular events occur, patients should seek immediate medical attention.  The cardiovascular status and risk factors of patients should be evaluated prior to therapy and cardiovascular monitoring and management should take place during treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17261, 0, 'Ponatinib', 'Water-Electrolyte Imbalance', 'Fluid retention occurs with BCR-ABL tyrosine kinase inhibitors therapy and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema.  Caution should be taken when using these drugs in patients with preexisting fluid retention or congestive heart failure.  Monitor and manage patients using standards of care.  Interrupt, reduce dose or discontinue therapy as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17262, 0, 'Ponatinib', 'Bone Marrow Failure Disorders', 'Thrombocytopenia, aplastic anemia, agranulocytosis and neutropenia occur with BCR-ABL tyrosine kinase inhibitors.  Therapy with these drugs should be administered cautiously in patients with preexisting bone marrow suppression.  A complete blood count should be performed every 1-2 weeks for the first month of therapy and then monthly thereafter, or as clinically indicated.  To manage myelosuppression, withhold, reduce dose, or discontinue therapy as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17263, 0, 'Ponatinib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17264, 0, 'Porfimer sodium', 'Esophageal Fistula', 'The use of photodynamic therapy (PDT) with porfimer is contraindicated for the treatment of esophageal cancer in patients with an existing bronchoesophageal or tracheoesophageal fistula.  Prior to administration of PDT, patients must be evaluated by barium swallow to rule out fistulas, which can occur with PDT, particularly if the esophageal tumor is eroding into the trachea or bronchial tree.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17265, 0, 'Porfimer sodium', 'Esophageal and Gastric Varices', 'Treatment with photodynamic therapy and porfimer should be conducted with extreme caution in patients with esophageal varices.  Light should not be given directly to the variceal area because of the high risk of bleeding.  In general, photodynamic therapy is not suitable for patients with esophageal or gastric varices, or patients with esophageal ulcers >1 cm in diameter.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17266, 0, 'Porfimer sodium', 'Porphyrias', 'The use of porfimer is contraindicated in patients with porphyria.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17267, 6129, 'Potassium bicarbonate', 'Dehydration', 'Administration of potassium salts in severe dehydration may predispose to renal impairment.  Therapy with potassium salts should be administered cautiously in patients with acute dehydration (e.g., due to severe or prolonged diarrhea or heat stress).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17268, 7499, 'Potassium bicarbonate', 'Dehydration', 'Administration of potassium salts in severe dehydration may predispose to renal impairment.  Therapy with potassium salts should be administered cautiously in patients with acute dehydration (e.g., due to severe or prolonged diarrhea or heat stress).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17269, 7523, 'Potassium bicarbonate', 'Dehydration', 'Administration of potassium salts in severe dehydration may predispose to renal impairment.  Therapy with potassium salts should be administered cautiously in patients with acute dehydration (e.g., due to severe or prolonged diarrhea or heat stress).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17270, 10619, 'Potassium bicarbonate', 'Dehydration', 'Administration of potassium salts in severe dehydration may predispose to renal impairment.  Therapy with potassium salts should be administered cautiously in patients with acute dehydration (e.g., due to severe or prolonged diarrhea or heat stress).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17271, 27129, 'Potassium bicarbonate', 'Dehydration', 'Administration of potassium salts in severe dehydration may predispose to renal impairment.  Therapy with potassium salts should be administered cautiously in patients with acute dehydration (e.g., due to severe or prolonged diarrhea or heat stress).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17272, 27130, 'Potassium bicarbonate', 'Dehydration', 'Administration of potassium salts in severe dehydration may predispose to renal impairment.  Therapy with potassium salts should be administered cautiously in patients with acute dehydration (e.g., due to severe or prolonged diarrhea or heat stress).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17273, 27131, 'Potassium bicarbonate', 'Dehydration', 'Administration of potassium salts in severe dehydration may predispose to renal impairment.  Therapy with potassium salts should be administered cautiously in patients with acute dehydration (e.g., due to severe or prolonged diarrhea or heat stress).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17274, 27132, 'Potassium bicarbonate', 'Dehydration', 'Administration of potassium salts in severe dehydration may predispose to renal impairment.  Therapy with potassium salts should be administered cautiously in patients with acute dehydration (e.g., due to severe or prolonged diarrhea or heat stress).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17275, 27134, 'Potassium bicarbonate', 'Dehydration', 'Administration of potassium salts in severe dehydration may predispose to renal impairment.  Therapy with potassium salts should be administered cautiously in patients with acute dehydration (e.g., due to severe or prolonged diarrhea or heat stress).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17276, 27136, 'Potassium bicarbonate', 'Dehydration', 'Administration of potassium salts in severe dehydration may predispose to renal impairment.  Therapy with potassium salts should be administered cautiously in patients with acute dehydration (e.g., due to severe or prolonged diarrhea or heat stress).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17277, 32222, 'Potassium bicarbonate', 'Dehydration', 'Administration of potassium salts in severe dehydration may predispose to renal impairment.  Therapy with potassium salts should be administered cautiously in patients with acute dehydration (e.g., due to severe or prolonged diarrhea or heat stress).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17278, 6129, 'Potassium bicarbonate', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17279, 7499, 'Potassium bicarbonate', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17280, 7523, 'Potassium bicarbonate', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17281, 10619, 'Potassium bicarbonate', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17282, 27129, 'Potassium bicarbonate', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17283, 27130, 'Potassium bicarbonate', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17284, 27131, 'Potassium bicarbonate', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17285, 27132, 'Potassium bicarbonate', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17286, 27134, 'Potassium bicarbonate', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17287, 27136, 'Potassium bicarbonate', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17288, 32222, 'Potassium bicarbonate', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17289, 6129, 'Potassium bicarbonate', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17290, 7499, 'Potassium bicarbonate', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17291, 7523, 'Potassium bicarbonate', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17292, 10619, 'Potassium bicarbonate', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17293, 27129, 'Potassium bicarbonate', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17294, 27130, 'Potassium bicarbonate', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17295, 27131, 'Potassium bicarbonate', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17296, 27132, 'Potassium bicarbonate', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17297, 27134, 'Potassium bicarbonate', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17298, 27136, 'Potassium bicarbonate', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17299, 32222, 'Potassium bicarbonate', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17300, 6129, 'Potassium bicarbonate', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
